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Simple Summary: Ovarian cancers (OCs) are the most lethal form of gynecological tumors. The 
commonest are high-grade serous OCs, while rare OCs originate from many different cell types, 
such as epithelial, germ cell, sex cord-stromal, or mixed types. Rare OCs have distinct molecular 
characteristics, prognosis, and therapeutic approaches. However, all ovarian malignancies mostly 
share the same problem: late diagnosis due to the lack of specific symptoms. Therefore, there is a 
perpetual need to discover better diagnostic, prognostic, and predictive biomarkers, as well as new 
therapeutic approaches. In recent years, long non-coding RNAs (lncRNAs) have gained widespread 
attention because of their important role in various biological pathways. They have multiple mech-
anisms of action with an important role in many cellular processes related to OCs development and 
progression. This review will focus on the different aspects of lncRNAs in OCs and attempt to high-
light the distinctive role of lncRNAs in common and rare OCs. 
Abstract: Rare ovarian cancers (ROCs) are OCs with an annual incidence of fewer than 6 cases per 
100,000 women. They affect women of all ages, but due to their low incidence and the potential 
clinical inexperience in management, there can be a delay in diagnosis, leading to a poor prognosis. 
The underlying causes for these tumors are varied, but generally, the tumors arise due to alterations 
in gene/protein expression in cellular processes that regulate normal proliferation and its check-
points. Dysregulation of the cellular processes that lead to cancer includes gene mutations, epimu-
tations, non-coding RNA (ncRNA) regulation, posttranscriptional and posttranslational modifica-
tions. Long non-coding RNA (lncRNA) are defined as transcribed RNA molecules, more than 200 
nucleotides in length which are not translated into proteins. They regulate gene expression through 
several mechanisms and therefore add another level of complexity to the regulatory mechanisms 
affecting tumor development. Since few studies have been performed on ROCs, in this review we 
summarize the mechanisms of action of lncRNA in OC, with an emphasis on ROCs. 
Keywords: rare ovarian cancers; long non-coding RNAs; lncRNAs; competing endogenous RNA; 
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Gynecologic malignancies comprise about 19% of all cancers diagnosed in women, 
and out of these more than 50% are classified as rare [1]. They encompass more than 30 
different histologic diagnoses of various sites, such as vulva, vagina, uterine cervix and 
corpus, fallopian tube, and ovary. Ovarian cancers (OCs) are the deadliest of all gyneco-
logical malignancies, and in 2020 there were around 314,000 new cases and 207,000 deaths 
related to them around the globe [2]. They mostly fall into the epithelial subtype based on 
the cell of origin, and the most malignant but also the most common type is the high-grade 
serous OC (HGSOC) [3]. Rare cancers are usually defined as malignancies that have an 
incidence of <6 cases per 100,000 [4]. Rare ovarian cancers (ROCs) are malignancies of the 
ovary which can originate from different cell types, such as epithelial, germ cell, sex cord-
stromal, or mixed types [5]. Ovarian malignancies mostly share the same problem, which 
is late diagnosis [6]. ROC malignancies lack distinguishable symptoms during the early 
stages of disease development, which means that most cancers are diagnosed late when 
they have already progressed to advanced stages of the disease and are therefore more 
difficult to treat. This is especially true for ROCs, as they can be misdiagnosed due to their 
rarity and clinical inexperience. This results in poor outcomes for these patients and 
stresses the need for reliable markers for early diagnosis and potential specific targets for 
therapy. In recent years, one class of macromolecules called long non-coding RNAs 
(lncRNAs) has been emerging as promising diagnostic and prognostic biomarkers, as well 
as potential therapeutic targets, for many different types of cancers [7]. Although the role 
of lncRNAs in OCs has been extensively reviewed previously [8–15], this is, to the best of 
our knowledge, the first effort to differentiate the role of lncRNAs between common and 
rare OCs. 
Generally, a major drawback in the research on ROCs is the lack of studies that sep-
arate the OC subtypes, as in most cases the samples are just classified as OC. Most studies 
examine OC in general or focus on the most prevalent HGSOC subtype. Even LGSOC is 
not well characterized within these studies, which makes analyzing available data diffi-
cult, and possibly misleading. Therefore, this review will outline the lncRNAs associated 
with OC in general, with the OC subtype defined where available, focusing on ROCs 
when possible. 
2. Common Versus Rare Ovarian Cancers 
OC is a major cause of morbidity and mortality in women, with minimal improve-
ment in survival rates over the past decades [16]. OC is divided into epithelial and non-
epithelial subgroups. However, OC is a heterogeneous malignancy with diverse patho-
physiology and clinical development. In the case of epithelial ovarian cancers (EOCs), the 
majority of tumors originate outside the ovary, while only a subset develops within the 
ovarian surface epithelium [17]. Approximately 90% of OCs belong to the malignant epi-
thelial tumor (carcinomas) group, and there are currently five main subtypes of carci-
noma: high-grade serous ovarian carcinoma (HGSOC), low-grade serous ovarian carci-
noma (LGSOC), endometrioid carcinoma; clear cell carcinoma, and mucinous carcinoma 
[18]. HGSOC and endometrioid cancers are considered common OCs, while the others are 
deemed to be rare. Table 1 summarizes the most common molecular alterations as well as 
the prognosis of different types of ovarian cancers. 
HGSOCs are chromosomally unstable tumors that commonly have mutations in the 
TP53 tumor suppressor gene [19]. In most cases, there are also germline or somatic muta-
tions in BRCA1 or BRCA2, or hypermethylation of BRCA1 promoter with a loss of expres-
sion. The underlying loss of BRCA1/2 function and inability to repair double-strand repair 
breaks, which in turn leads to chromosomal instability, lead to a potential role for drugs 
targeting the DNA repair (e.g., PARP inhibitors) [20]. The PI3K-AKT pathway plays an 
important role in HGSOC [3]. The 5-year overall survival rates are 84.0%, 67.7%, and 32.1% 
for stage IA/IB, IC/II, and III/IV HGSOC, respectively [21]. 
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ity (MSI-H), KRAS, 
CTNNB1, or APC 
WNT 
Worse than Advanced 
Stage Serous Cancer 
[23,26–28] 
Non-Epithelial      
Sex-Cord Stromal Tumors 





Sex-Cord Stromal Tumors 
(Sertoli–Leydig Cell Tu-
mors) 
Rare DICER1, FOXL2 Unknown Good [33] 
Germ-Cell Tumors Rare KIT, KRAS Unknown Unknown [34] 
Endometrioid carcinomas (EC) are the second commonest malignant ovarian neo-
plasm, accounting for 8–15% of all ovarian carcinomas. There is a strong association with 
endometriosis. Most EC is grade 1 or 2. Since at presentation they are predominantly low 
stage and low grade, the burden of morbidity and mortality associated with this subtype 
is relatively low, despite being common. The 5-year overall survival rates are 87.1%, 
83.9%, and 44.7% for stage IA/IB, IC/II, and III/IV EC, respectively [21]. There are no data 
currently available specifically on the benefit of adjuvant chemotherapy in patients with 
advanced-stage EC, and such data will be hard to acquire given the rarity of advanced-
stage or recurrent tumors. Genes that are typically mutated in EC include CTNNB1, 
CDKN2A, PIK3CA, KRAS, ARID1A, PTEN, and PPP2R1A [20]. Moreover, the MAPK/RAS, 
WNT, and PI3K pathways could be good candidate targets for molecular therapeutics 
[35]. 
LGSOC represent <5% of all ovarian serous carcinomas, affecting younger women 
with a median age of under 55 years. The 5-year overall survival rates are 93.2%, 82.7%, 
and 54.2% for stage IA/IB, IC/II, and III/IV LGSOC, respectively [21]. Despite its slow 
growth, there is a poor sensitivity of LGSOC to chemotherapy. In this type of malignancy, 
there are mutations of genes involved in the mitogen-activated protein kinase (MAPK) 
pathway, such as BRAF, KRAS, NRAS, and ERBB2, but occasionally there may be driver 
mutations of FFAR1, PIK3CA, USP9X, and EIF1AX linked to the AKT-mTOR pathway 
[22]. Moreover, RAD50 and NBS1 proteins are absent in LGSOC. Since estrogen and pro-
gesterone receptors are often expressed in LGSOC, hormone therapy can be a potential 
therapeutic alternative. Targeted therapy such as trametinib, a mitogen-activated protein 
kinase inhibitor, could represent a new standard of care treatment option for women with 
recurrent LGSOC. 
Ovarian clear cell carcinoma (OCCC) accounts for approximately 5% of all ovarian 
carcinomas. When diagnosed at an earlier stage, it tends to have a good prognosis as sur-
gery is often curative. In advanced stages, however, it is associated with a poor prognosis 
as it is often chemoresistant [23]. The 5-year overall survival rates are 81.7%, 69.0%, and 
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22.3% for stage IA/IB, IC/II, and III/IV OCCC, respectively [21]. OCCC and clear-cell car-
cinoma of the kidneys share similar molecular pathways [24], and therefore targeted ther-
apy aiming to inhibit angiogenesis, growth-factor signaling, and mTOR pathways might 
improve prognosis. Although preliminary clinical data focusing only on OCCC are lim-
ited, treatment with multikinase inhibitors (axitinib, sunitinib, sorafenib, and pazopanib), 
bevacizumab, temsirolimus, and everolimus may have anti-tumor activity in this partic-
ular malignancy. In OCCC, the most common somatic genetic alterations are loss of 
ARID1A, activation of PIK3CA, and mutations in PPP2R1A and KRAS [25]. Novel treat-
ment strategies in the case of ARID1A mutated OCCC include the inhibition of the me-
thyltransferase EZH2 and the administration of dasatinib and/or the HDAC6 inhibitor 
ACY1215. Since EGFR expression is detected in up to 60% of OCCC cases, EGFR inhibitors 
may also be effective. In addition, mTOR inhibitors may also be promising due to the high 
expression of mTOR in both early- and advanced-stage OCCC [27]. 
Mucinous epithelial ovarian cancer (MOC) accounts for less than 5% of EOCs. The 5-
year overall survival rates are 82.9%, 69.,5%, and 13.9% for stage IA/IB, IC/II, and III/IV 
OCCC, respectively [21]. While it is recommended to treat MOC with adjuvant car-
boplatin and paclitaxel, since HER2 is amplified or expressed in up to 19% of cases, 
trastuzumab and HER2- targeted therapies might be an effective treatment [23,26]. Mo-
lecular alterations in MOCs commonly involve KRAS, as well as mutations in CTNNB1 or 
APC gene, and high microsatellite instability (MSI-H) [28]. 
Sex-cord stromal tumors and malignant germ-cell tumors are very rare non-epithelial 
ovarian tumors, which overall account for only 6% of all ovarian malignancies [36–39]. A 
common type of malignant sex-cord stromal tumor is granulosa cell tumor (GCT), of 
which there are the adult type and juvenile granulosa cell tumors. Granulosa cell tumors 
secrete progesterone and estrogen [29]. Testing for the FOXL2 c.402C > G (p.C134W) mu-
tation is helpful in the diagnosis of adult-type tumors [30]. However, GATA4, SMAD, 
VEGF, PI3K/AKT, AMH, and TGF-β are also involved in this type of cancer [31]. Granu-
losa cell tumors tend to have a slow progression and late recurrence. In the case of women 
with advanced-stage or recurrent granulosa cell tumors, traditional chemotherapy is lim-
ited in effectiveness [40]. Carboplatin and paclitaxel, a combination of bleomycin, etopo-
side, and cisplatin (BEP), and targeted therapies including VEGF inhibitors, tyrosine ki-
nase inhibitors (TKIs), and hormonal treatment have been investigated as possible thera-
peutic options [23]. For Sertoli–Leydig cell tumors, DICER1 mutations seem to be a prog-
nostic factor that is associated with a higher risk of relapse, especially in younger patients. 
In these tumors, adjuvant chemotherapy is recommended in stage IA disease particularly 
if there is poor differentiation or heterologous elements. BEP is commonly used, or else 
etoposide/cisplatin, carboplatin, and paclitaxel, cyclophosphamide/doxorubicin/cisplatin, 
or platinum agents alone. The 5-year overall survival rates are 90.7% and 76.2% for gran-
ulosa cell tumors and Sertoli-Leydig cell tumors, respectively [41]. 
Germ-cell tumors can be histologically classified as dysgerminoma, immature tera-
toma, yolk sac tumor, choriocarcinoma, embryonal carcinoma, mixed germ-cell tumor, 
malignant struma ovarii, gonadoblastoma, and teratoma with malignant transformation 
[18]. They are different from EOCs because they tend to be diagnosed in younger women, 
and due to their rapid tumor growth, they are usually symptomatic, thus leading to earlier 
diagnosis and a significantly better prognosis. Germ-cell tumors also have a different set 
of biomarkers such as alpha-fetoprotein (AFP), serum human chorionic gonadotropin 
(HCG), and lactate dehydrogenase (LDH) [42]. The most common mutations were found 
in KIT and KRAS, akin to testicular germ cell tumors [34]. Platinum-based regimens have 
led to a 5-year overall survival of over 90% for early-stage tumors and above 75% for ad-
vanced disease [37]. Adjuvant chemotherapy such as BEP is being used routinely. In the 
case of relapsed ovarian germ-cell tumors, treatment includes the use of paclitaxel, 
ifosfamide, and cisplatin, with extrapolation from current treatment used for testicular 
germ-cell tumors, and even using more complex regimens containing combinations of 
methotrexate, cisplatin, vincristine, and bleomycin, alternating with cyclophosphamide, 
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etoposide and actinomycin D [36]. Furthermore, targeted therapies that have been inves-
tigated consist of trastuzumab (anti-HER2 monoclonal antibody, tyrosine kinase inhibi-
tors (TKIs) (i.e., imatinib and sunitinib), and antiangiogenic agents such as thalidomide 
and bevacizumab [29]. 
In contrast to almost all other common OCs, the treatment of ROCs is challenging 
and often must be based on expert opinion, retrospective studies, or extrapolation from 
other tumor sites with similar histology. This leads to difficulty in developing effective 
guidelines for clinical practice. 
Availability of Cell Culture Models for Studying Common and Rare Ovarian Cancers 
Cancer and its corresponding healthy tissue cell lines are indispensable in vitro mod-
els for discovering new biomarkers and pre-clinical drug testing. Due to its extreme het-
erogeneity, there are many problems with using OCs cell lines as models for so many 
different OCs subtypes. One of the biggest problems is often misclassification of com-
monly used cell lines with respect to their tumor subtype [43]. Domcke et al., analyzed a 
panel of 47 commonly used OC cell lines and found significant genetic differences be-
tween them and HGSOC tumor tissue samples, while several less frequently used cell 
lines were found to be more genetically alike to the primary tumors [44]. A collection of 
25 rigorously validated OC cell lines was reported to properly represent the OC subtypes 
from which they are derived [45]. Just recently, Barnes et al., used non-negative matrix 
factorization on transcriptomic data of 44 EOC cell lines to properly classify them into the 
five major histologically distinct subtypes (HGSOC, LGSOC, EC, OCCC, and MOC) [46]. 
All this pointed out an inevitable use of comprehensive omics techniques for proper clas-
sification of cell lines as models for tumor types which they represent. For instance, a ge-
nome-wide analysis of 45 OC cell lines, including some rare subtypes, revealed that these 
cell lines were largely representative of primary ovarian cancers. Analysis of mutation 
signatures demonstrated that serous, mucinous, and undifferentiated tumor subtypes 
showed the age-related signature, while clear cell and serous OCs also had a mismatch 
repair-associated signature. The most frequently mutated gene is TP53, followed by 
ARID1A, PIK3CA, SMAD4, KRAS, APC, CREBBP, and PPP2R1A. Frequent deletions in-
clude CDKN2A, CDKN2B, ERBB4, NF1, NF2, CDC73, EZH2 and STK11 [47]. This is some-
what consistent with the data available from The Cancer Genome Atlas (TCGA) project, 
which encompasses 489 HGSOC samples. The most frequently mutated gene in this da-
taset is also TP53, followed by NF1, BRCA1, BRCA2, RB1, and CDK12 [48]. TCGA analysis 
also revealed that somatic copy number abnormalities are common in HGSOC, resulting 
in frequent amplification of CCNE1, MYC, and MECOM genes, and deletions of PTEN, 
RB1, and NF1 [48]. Methylation analysis revealed increased promoter hypermethylation 
of AMT, CCL21, SPARCL1, RAB25, and BRCA1 [48]. Considering the limitations of the 
TCGA subset, an omics-wide integrated analysis was performed on 96 primary invasive 
early-stage OCs divided into OCCC, EC, HGSOC, LGSOC, and MOC. Unique DNA meth-
ylation patterns were identified for each subtype, with OCCC showing the highest meth-
ylation, and HGSOC the lowest. MOC showed the highest average number of copy num-
ber alterations. RNA expression was able to classify the different histotypes, but the dif-
ferences were more evident when using the DNA methylation heatmap [49]. 
One of the best and largest resources on cell lines is the Cellosaurus 
(https://web.expasy.org/cellosaurus/) (accessed on 7 October 2021) [50]. Furthermore, the 
Cancer Cell Line Encyclopedia (https://sites.broadinstitute.org/ccle/) (accessed on 7 Octo-
ber 2021) [51] and the COSMIC Cell Line Project (https://cancer.sanger.ac.uk/cell_lines) 
(accessed on 7 October 2021) [52] contain many different omics information obtained from 
cell lines. However, not all OC cell lines in those two databases are fully classified, so a 
combined survey of different databases and original publications is needed to discover to 
which OC subtype a cell line of interest belongs. 
3. Long Non-Coding RNAs: Classification and Mechanisms of Action 
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Non-coding RNAs (ncRNAs) are a large class of RNA molecules that are translated 
but do not encode proteins. This class includes a wide range of different RNA molecules, 
which can be broadly classified into infrastructural ncRNAs and regulatory ncRNAs. In-
frastructural ncRNAs include transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), and 
small nuclear RNAs (snRNAs) and their functions are well-known and have been exam-
ined in detail [53]. Regulatory ncRNAs include molecules such as small nucleolar RNAs 
(snoRNAs), microRNAs (miRNAs), small interfering RNAs (siRNAs), P-element-induced 
wimpy testis interacting (PIWI) RNAs (piRNAs), and long non-coding RNAs (lncRNAs). 
SnoRNAs, miRNAs, and piRNAs are collectively named small non-coding RNAs 
(sncRNAs). 
LncRNA molecules are transcribed by RNA Polymerase II and processed in a way 
that resembles mRNA processing, as they are often 5′ capped, 3′ polyadenylated, and 
spliced similarly to mRNAs [54]. It has been demonstrated that 98% of lncRNAs are 
spliced [55], while only 40% of lncRNA transcripts are non-polyadenylated [56,57]. Fur-
thermore, lncRNAs show a bias toward two-exon transcripts, with slightly longer exons 
and longer introns than protein-coding genes which are often alternatively spliced. Their 
level of expression is generally lower than that of protein-coding genes and is more tissue-
specific [55,58,59]. 
Biogenesis of lncRNAs is based on their location in respect to protein-coding genes, 
and lncRNAs can thus be classified into four categories: (1) long intergenic non-coding 
RNAs (lincRNAs), transcribed intergenically from both strands; (2) sense intronic tran-
scripts, located within introns of coding genes without intersecting with exons; (3) sense 
overlapping transcripts, which overlap with the exons of coding genes on the same strand; 
and (4) antisense RNAs, which are located within the exons and introns of protein-coding 
genes but on the opposite strand (so-called natural antisense transcripts or NATs) (Figure 
1) [60–63]. The majority of lncRNA loci are located in intergenic regions [55]. A detailed 
explanation of lncRNA biogenesis can be found in [64]. 
 
Figure 1. Categories of lncRNAs based on their location in respect to protein-coding genes. (A) Long intergenic non-coding 
RNAs (lincRNA) are transcribed intergenically from both strands. (B) Sense intronic transcripts are located within introns 
of coding genes without intersecting with exons. (C) Sense overlapping transcripts overlap with the exons of coding genes 
on the same strand. (D) Antisense RNAs are located within the exons and introns of protein-coding genes but on the 
opposite strand. Created with BioRender.com. 
Mutations and genomic rearrangements can affect the expression of lncRNA in the 
same way as they affect the protein-coding genes and can contribute to tumorigenesis. 
Aznaourova et al., have summarized a list of lncRNAs involved in various human dis-
eases, including gynecological cancers [65]. Regulation of tumor progression by lncRNA 
can occur through modification of several mechanisms: the epigenetic regulation of genes 
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(chromatin remodeling, histone modification, DNA methylation), the transcriptional reg-
ulation of genes (cis-regulation of nearby genes or trans-regulation of distant genes), and 
post-transcriptional regulation of gene expression (alternative splicing of pre-mRNA, sta-
bilization of mRNA, and translation and stabilization of proteins) [7]. 
Initial systematic large screening of lncRNA genes, using genome-wide chromatin-
state maps by immunoprecipitation, identified over a thousand highly conserved 
lncRNAs [66]. The current estimate of the number of genes encoding lncRNA according 
to the GENCODE and FANTOM projects is between 17,957 and 27,919 genes [67]. Their 
functions are classified as either (1) RNA-based, where lncRNA interacts with DNA, RNA, 
or proteins, (2) gene-regulatory, where lncRNA modifies the activity of regulatory ele-
ments, or (3) transcription-based, where the process of transcription influences gene ac-
tivity [67]. They can function as signals, decoys, guides, or scaffolds (Figure 2) [7]. 
LncRNAs are considered to signal molecules when they regulate the transcription of 
target genes. In this context, lncRNA can exert this effect alone, or in combination with 
transcription factors. Their expression is triggered by specific conditions, and they in turn 
trigger specific responses to those conditions. The best-known example of this type of reg-
ulation is the lncRNA XIST, which is involved in X-chromosome inactivation by direct 
interaction with the chromatin [68]. Other examples include lncRNA HOTAIR, which is 
transcribed from the homeobox transcription factor cluster (HOX) in tightly controlled 
conditions; PANDAR, which is induced by DNA damage; LINC-ROR, which is associated 
with reprogramming to induced pluripotent stem cells; and COLDAIR, which is induced 
by cold [69]. 
When acting as decoys, they usually block specific molecular pathways by binding 
to a specific protein or RNA and impairing its function. This is the most common type of 
regulation that lncRNAs exert on their targets. The targets are most often miRNA mole-
cules, and lncRNAs antagonize the miRNA they target by sequestering the miRNA away 
from their intended mRNA targets [69]. Competing endogenous RNAs (ceRNAs) or “mo-
lecular sponges” act as competitive inhibitors which block the activity of the target 
mRNAs. Most often this mechanism acts to “sponge” various miRNA molecules, thereby 
removing them from their intended targets and suppressing their effect [70]. 
 
Figure 2. Functional roles of lncRNAs. (A) As signal molecules, lncRNAs act either alone or in combination with proteins 
like transcription factors to mediate the transcription of downstream genes; (B) As decoys, lncRNAs either bind to func-
tional proteins to block their activity or compete with mRNAs for binding to miRNAs to block their inhibitory effects on 
mRNAs; (C) As guides, lncRNAs carry and locate functional proteins in the target area to perform their functions; (D) As 
scaffolds, lncRNAs guide different types of macromolecules to assemble complexes and facilitate their interactions. Cre-
ated with BioRender.com. 
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Guide lncRNAs direct the localization of ribonucleoprotein complexes to specific tar-
gets. This effect can be achieved in cis, when they affect neighboring genes, or in trans 
when the effect is on distant genes. These effects are mediated through changes in the 
structure of chromatin. Regulation in cis involves specific interaction between the lncRNA 
and chromatin at its promoter, leading to accumulation of proteins involved in histone 3 
lysine 9 (H3K9) methylation and gene silencing. Regulation in trans often targets proteins 
of the Polycomb Repressive Complex (PRC) and changes their localization, activity, and 
occupancy, leading to changes in chromatin structure in trans. HOTAIR is one such 
lncRNA, often found overexpressed in tumors and associated with cancer metastases [69]. 
When acting as scaffolds, they facilitate the interaction of different molecules and 
proteins. CDKN2B-AS1, a lncRNA located in the INK4b/ARF/INK4a locus, recruits multi-
ple chromatin-modifying proteins and thereby modulates transcriptional activity of the 
locus [69]. It is important to emphasize that lncRNAs employ more than one mechanism 
of action to exert their effects, so one function does not necessarily exclude all others. 
There are potentially other yet undescribed mechanisms by which lncRNAs can affect 
gene and protein expression and function. 
Even though lncRNAs were originally defined as RNA which do not encode proteins, 
recent reports suggest that some lncRNAs contain open reading frames (ORF) and may 
encode peptides [71]. These peptides are involved in various signaling processes, e.g., 
mTOR signaling, regulation of Ca2+-ATPase, mRNA decay, and mitochondrial activity. 
They can also be involved in metabolic reprogramming of several cancers, such as colon, 
liver, esophageal, and breast cancer, and melanoma [71]. Furthermore, lncRNAs can also 
encode miRNAs, as exemplified by miR-675 which is transcribed from exon 1 of H19 [72]. 
4. Intracellular and Extracellular Compartmentalization of lncRNAs 
LncRNAs can be found in different cellular compartments, from the nucleus to cyto-
plasm and mitochondria, and even exported from the cell via exosomes. About 30% of 
lncRNAs are located in the nucleus, where they can interact with transcription factors, 
chromatin complexes, and heterogenous ribonucleoprotein complexes [73]. Within the cy-
toplasmic compartment, lncRNAs can be found in many structures and organelles. 
LncRNAs in ribosomes are most often associated with nonproductive initiation of trans-
lation, but small peptides may be produced from open reading frames in individual 
lncRNA. Additionally, lncRNAs in the ribosome may act as regulators of translation [74]. 
So far, several lncRNAs that are transcribed from the mitochondrial genome, and about 
20 nuclear-encoded lncRNAs that affect mitochondrial biology have been described [75]. 
These include some ubiquitous lncRNAs that are involved in many oncogenic processes, 
such as SAMMSON, HOTAIR, H19, HOTTIP, and MEG3, but also some specific ones, like 
CEROX1 (cytoplasmic endogenous regulator of oxidative phosphorylation 1), which af-
fects the process of oxidative phosphorylation. Mitochondria-encoded lncRNAs are either 
antisense mitochondrial transcripts, like lncND5, lncND6, lncCYB, and MDL1AS; chimeric 
mitochondrial transcripts, like ASncmtRNA-1 and ASncmtRNA-2; or putative mitochon-
drial DNA-encoded lncRNAs, like LIPCAR [75]. 
Exosomes are bi-layered membrane vesicles secreted from the cells, 30–150 nm in 
diameter, which can contain a wide range of molecules usually found within the cells. 
They are generated by the budding of the endosomal membrane. LncRNAs are packed 
inside exosomes whereby they interact with RNA-binding proteins through specific mo-
tifs. Exosomes are used in cell-to-cell communication, and whatever is packed inside an 
exosome may be delivered to a receiving cell and trigger a specific molecular response in 
that cell. In the case of tumor-derived exosomes, these responses range from tumor 
growth, invasion, and metastasis to angiogenesis and reprogramming of the tumor mi-
croenvironment. Furthermore, several lncRNAs (UCA1, FAM225A, RAMP2-AS1, 
POU3F3, HOTAIR, CCAT2) have been identified that affect the endothelial cells of blood 
vessels and stimulate angiogenesis [76]. The cancer-associated fibroblasts-derived exo-
somes were shown to carry lncRNA H19, which is highly expressed in tumor stroma in 
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comparison to tumor tissue. This lncRNA promotes stemness and chemoresistance of can-
cer cells and increases the frequency of tumor-initiating cells [77]. 
5. The Role of lncRNAs in Various Biological Processes Related to Ovarian Carcino-
genesis 
Each hallmark of cancer can be modulated by lncRNA activity, thus leading to in-
creased proliferation, viability, growth suppression, motility, immortality, and angiogen-
esis [78]. It has been debated whether lncRNAs can act as initiators of tumorigenesis, or if 
they are dysregulated as a consequence of tumorigenesis. The Cancer LncRNA Census 
contains a compilation of 122 GENCODE lncRNAs associated with the initiation of tu-
morigenesis, some (63.1%) acting as oncogenes, some (28.7%) as tumor suppressors, and 
some (8.2%) with evidence of both activities depending on tumor type. LncRNAs HO-
TAIR, MALAT1, MEG3, and H19 are associated with a large number of cancer types [79]. 
The same study identified tumor-causing mutations in several lncRNAs, supporting their 
role in tumor initiation [79]. A recent literature survey of Salamini-Montemurri et al., has 
identified 215 lncRNAs being involved in OCs, of which for 157 there is experimental 
proof [8]. Apart from initiation, lncRNAs have been associated with many biological pro-
cesses associated with metastasis [80], such as the immune response [73], radiation re-
sponse [81], epithelial to mesenchymal transition (EMT) and stemness [82], cell-to-cell 
communication, and regulation of the microenvironment in which cells reside [77]. 
It is generally said that in the context of OC, there is proof that lncRNAs are involved 
in all the hallmarks of cancer except ‘genomic stability and mutation’ and ‘enabling repli-
cative immortality’ [8]. Several lncRNAs showed influence on the size and weight of ovar-
ian tumors in vivo, such as AB073614 [83], EPB41L4A-AS2 [84], GAS5 [85], LINC00565 [86], 
TINCR [87] and TPT1-AS1 [88]. Loss of cell cycle control, related to proliferative signal 
maintenance and evasion of growth suppressors, is in OC associated with lncRNAs 
MNX1-AS1 [89], SPRY4-IT [90], KB-1471A8.2 [91], and CASC15 [92]. Avoidance of cell 
death which causes cell immortalization has mostly been studied in the context of apop-
tosis. It was shown that lncRNA LNCRNA-ATB [93] can regulate apoptosis in OC. Also, 
GAS5 can trigger a highly inflammatory type of programmed cell death called pyroptosis 
[94], while some lncRNAs can either induce (MEG3 [95] and MALAT1 [96]) or inhibit (HO-
TAIR [97], HULC [98] and RP11-135L22.1 [99]) autophagy in OC. Some lncRNAs can con-
trol cancer cell metabolism by regulating key enzymes in metabolic pathways, mainly 
stimulating glycolysis (the Warburg effect) [100]. For instance, it was shown in OC that 
lncRNAs LINC00504 [101], NRCP [102], LINC00092 [103], and H19 [104] can activate dif-
ferent enzymes in the glycolysis pathway from glucose to pyruvate. It has been shown 
that MALAT1 promotes angiogenesis in OC by inducing the expression of VEGF and FGF 
[105], while DANCR [106] and HNF1A-AS1 [107] can promote it by inducing VEGF and 
SEMA4D expression. 
LncRNAs play a role in the regulation of immune response, where they are involved 
in several mechanisms of action. A major role is antisense silencing associated with DICER 
and molecular sponge function for reducing the regulatory effects of miRNAs [73]. Many 
stages of the immune response can be targeted and regulated by lncRNAs. Tumor antigen 
release, more specifically, the expression of chaperone calreticulin, can be inhibited by 
lncRNA expressed from the RB1 promoter (RB1-DT). Antigen presentation can be affected 
by the specific reduction of the abundance of antigen-presenting cells (lincRNA 
LINC01139) or by the regulation of pro-inflammatory cytokines. EGILA can affect the dif-
ferentiation of T lymphocytes, thereby affecting immune cell priming and activation. 
LncRNAs can also affect immune cell migration and infiltration, and affect recognition 
and attack of cancer cells [108]. HOTTIP was cited as the only lncRNA associated with the 
avoidance of immune surveillance by increasing IL6 expression in ovarian tumor cells, 
which triggers PD-L1 expression through the STAT3 pathway in neutrophils [109]. There-
fore, targeting specific lncRNAs or modifying their activity to boost the immune response 
or increase recognition of tumor cells may be a potential therapeutic approach in ROCs. 
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Resistance to radiation can be modulated positively and negatively by the lncRNAs. 
Some lncRNAs, such as GAS5, increase the radiosensitivity of cancer cells through their 
sponging mechanisms. In contrast, other lncRNAs, such as HOTAIR or TUG1, can increase 
radioresistance by sponging specific miRNAs. Expression of lncRNAs can also be used as 
biomarkers of radiation damage, as lncRNA TP53COR1, TUG1 and MEG3 have been 
found to be upregulated after radiation damage by multiple studies [81]. Increasing the 
radiation sensitivity of tumor cells or increasing radiation resistance in healthy tissues by 
targeting specific lncRNA targets could be a promising approach for the treatment of var-
ious cancers, including ROCs. 
EMT is a reversible process during which epithelial cells acquire mesenchymal char-
acteristics, including reduction of cell-cell contacts, changes in cell morphology, and in-
crease of migratory capability. This transition is considered one of the crucial steps during 
tumor invasion and metastasis. The process is reversible, and under the right conditions, 
the cells can transition back from mesenchymal to the epithelial phenotype, resulting in 
mesenchymal to epithelial transition (MET). EMT process is regulated by specific tran-
scription factors such as SNAIL, SLUG, TWIST1, TWIST2, ZEB1, and ZEB2 [110]. Cancer 
stem cells (CSC) are a subpopulation of tumor cells with the capacity for self-renewal, 
asymmetric division, and multipotency. This stemness phenotype is often acquired 
through the EMT process and regulated by transcription factors SOX2, OCT4, NANOG, 
KLF4, and LIN-28. Many of these EMT and CSC regulators can be controlled by lncRNA 
such as HOTAIR, H19, MALAT1, LINC-ROR, HOTTIP, NEAT1, LNCRNA-ATB, and others 
[82]. 
Cell-to-cell communication and the microenvironment are important factors during 
tumor progression and metastasis. Tumor cells interact with their environment and vari-
ous cell types in their surroundings. The most abundant and relevant cell types in this 
microenvironment are the cancer-associated fibroblasts (CAF), which respond to the cy-
tokines produced by the tumor to support tumor growth and dissemination. Many 
lncRNAs are upregulated in the CAF compared to normal fibroblasts, such as MALAT1, 
NEAT1, H19, GAS5, and MEG3 [77,111]. The communication also goes in the opposite di-
rection, from tumor cells to fibroblasts, reprogramming them into CAF-like cells [77]. In-
terrupting this cell-to-cell communication between tumor and stromal cells through 
lncRNAs is also a promising approach to tumor treatment, as the microenvironment plays 
a major role in the ability of tumors to grow, progress, and ultimately metastasize. 
Post-translational modifications (PTMs) of proteins are involved in several biological 
phenomena including signaling processes that occur at different stages of tumor develop-
ment [112,113]. Although the mechanism of action is not fully discovered, change in the 
PTMs affects protein activity, stability, protein-protein, and protein-nucleic acid interac-
tions. 
LncRNAs interfere with PTMs in the cytoplasm [114]. They may downregulate the 
PTMs by interacting with enzymes involved in PTMs and/or blocking the modification 
sites. The size of PTMs and associated proteoforms in biological systems are too large and 
there is no model system that shows the dynamic interactions in diseases. However, In-
cRNA-interacting genes obtained from bioinformatical analyses can be used to assess the 
potential IncRNA-PTMs relationship in OC. 
Histones are subjected to several PTMs including methylation, acetylation, phos-
phorylation, and ubiquitination [115]. It has been previously shown that methyl-CpG-
binding domain protein 1 (MBD1) interacts with H19 through repressing the methylated 
regions. It also affects the adjacent insulin-like growth factor 2 gene and associated pro-
teins [114]. Both alterations in MBD1 [116] and insulin-like growth factors are linked to 
OC. Histone acetylation is another key chromatin modification causing epigenetic varia-
tion that is implicated in OC pathogenesis [117,118]. LncRNAs can change this process 
either by interrupting the histone acetylation process, such as LNCPRESS1 binding to 
SIRT6 and preventing its binding to histones [119], or by acting as scaffolds regulating 
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histone acetylation and methylation, such as GClnc1 which acts as a scaffold for WDR5, 
and KAT2A proteins [120]. 
It is well-known that phosphorylation of proteins is one of the most common mech-
anisms that regulate protein activity, and phosphorylation is often dysregulated in cancer. 
AKT and mTOR phosphorylation have been detected as potential biomarkers for OC and 
tumor growth [121]. LncRNA-AKT interactions were experimentally shown in lung cancer 
[122] which might be a sign for similar connections for other cancers including ovarian. 
The majority of the proteins are glycosylated and glycosylation plays a crucial role in 
cancer biology [122] and serves both as a diagnostic and prognostic biomarker for OC 
[122–125]. Protein-specific glycosylation studies have discovered changes in Immuno-
globulin G (IgG), haptoglobin beta-chain, alpha1-acid glycoprotein, and alpha1-antichy-
motrypsin glycosylation in OC [126]. Although the role of IncRNAs has not been com-
pletely explored in OC, a link between lincRNAs and N-Glycosylation of IgG has been 
detected [127]. 
Both bioinformatical and experimental studies have discovered that lncRNAs 
prompt PTMs at different levels. The outcomes need to be further investigated to unravel 
the possible mechanisms leading to accurate diagnosis and effective treatments. 
LncRNAs, primarily through their crosstalk with miRNAs, regulate the osteogenic 
differentiation of mesenchymal stem cells (MSCs), a population of stromal cells in the 
bone marrow, and other anatomical regions such as adipose tissue and apical papilla of 
the tooth [128]. MSCs are capable of self-renewal and differentiation into multiple cell 
lineages, of which osteoblasts are important for bone development, homeostasis, and re-
generation [129]. Their differentiation is mediated by several signaling pathways of which 
TGF-β/BMP and WNT/β-catenin pathways are central [130]. Interestingly, several 
lncRNAs which were found to be differentially expressed in OCs, such as H19, NEAT1, 
MALAT1, HOTAIR, or XIST, participate in this cellular process [131]. Although osteogenic 
differentiation is primarily associated with the development of osteosarcoma [132], MSCs 
could be recruited to the tumor microenvironment and can both restrict [133] and promote 
solid tumor growth [134]. In OCs, carcinoma-associated MSCs have been identified in 
ovarian tumor tissue samples and it was proven that they can regulate ovarian cancer 
stem cells proliferation and tumorigenesis through altered production of BMP [135]. It 
was also shown that umbilical cord MSCs inhibited the growth of EC cell line TOV-112D 
[136], while bone marrow MSCs reduced the growth rate of cisplatin-resistant EC SKOV3 
cells [137]. Bu et al. showed that also endometrial MSCs derived from human menstrual 
blood can attenuate tumor growth of EC cell line SKOV3 and postulated that observed 
intrinsic anti-tumor properties of adult MSCs could be utilized for developing an MSC-
based therapy for treating OCs [138]. 
6. LncRNAs Associated with Common and Rare Ovarian Cancers 
TCGA data has been used to analyze lncRNA in different tumor types, but OC has 
not been analyzed in more detail because the TCGA database lacks the appropriate 
healthy tissue controls for HGSOC samples, thus making the differential expression anal-
ysis impossible for OC [139,140]. However, somatic copy number alterations are frequent 
in OC, and lncRNA BCAL8 has been found amplified in breast cancer and associated with 
poor clinical outcomes of OC [139]. HGSOC can be divided into four distinct subtypes: 
immunoreactive, characterized by CXCL11, CXCL10, and CXCR3 expression; differenti-
ated, characterized by MUC16 and MUC1 expression; proliferative, characterized by 
HMGA2, SOX11, MCM2, and PCNA overexpression and MUC1 and MUC16 downregu-
lation; and mesenchymal, characterized by high expression of HOX genes, FAP, ANGPTL2 
and ANGPTL11 [48]. Mesenchymal subtypes often show upregulation of MIAT (also 
known as gomafu in humans), proliferative types show downregulation of NEAT1 and 
UCA1, while serous subtypes show frequent amplification of OVAL [140]. 
Several lncRNAs have been found to have an effect in a wide range of human cancers, 
including many gynecological cancers. In OC, a specific signature of six lncRNA has been 
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identified by a bioinformatical analysis. This signature associates RUNX1-IT1, MALAT1, 
H19, HOTAIRM1, LOC100190986, and AL132709.8 lncRNAs [141]. Of these, MALAT1 and 
H19 have been extensively studied in OC, along with several other lncRNAs: HOTAIR, 
NEAT1, XIST, MEG3, and UCA1. Most extensively analyzed lncRNAs in OC have been 
listed in Table 2, and the lncRNAs more specific for ROCs are summarized in Table 3. 
6.1. H19 
A locus for the H19 imprinted maternally expressed transcript produces a 2.3 kb long 
RNA transcript, which is abundantly expressed during embryonic development and 
downregulated after birth. It is a paternally imprinted gene, but imprinting loss, and sub-
sequent overexpression, have been associated with ovarian tumors [142,143]. Knockdown 
of this lncRNA promotes G2/M cell cycle arrest, induces apoptosis of OC cells, and inhibits 
cell growth [143]. H19 can act as a competing endogenous RNA of miR-370-3p, resulting 
in the promotion of TGFB1-induced EMT [144], and as an inhibitor of a tumor-suppressor 
miRNA let-7, resulting in increased tumor cell migration and invasion [145]. H19 is ele-
vated in OC cells resistant to cisplatin [146]. Its downregulation leads to increased sensi-
tivity to cisplatin [147,148]. Polymorphisms in the H19 locus are associated with platinum-
based chemotherapeutic response [149]. H19 can also affect cancer cell metabolism, 
through the sponging effect of miR-324-5p, which regulates PKM2, a major contributor to 
the Warburg effect [104]. Although most of these studies were performed on serous epi-
thelial ovarian cancer cell lines, the role of H19 has also been examined in some ROCs. 
H19-overexpressing choriocarcinoma cells were found to be more tumorigenic in vivo, 
even though there was no difference in their clonogenicity in the in vitro assays. There is 
a selection of cells expressing high levels of H19 during the microevolution of tumor pro-
gression, which suggests that this lncRNA does not act as a tumor-suppressor [150]. Loss 
of H19 imprinting has also been demonstrated in pediatric germ cell tumors, and it may 
reflect the origin of these tumors in different stages of germ cell development [151–153]. 
Benign ovarian teratomas show a varying degree of H19 hypomethylation, and DNA pre-
pared from cultured teratoma cells shows extreme hypomethylation of the H19 locus 
[154]. Ovarian granulosa cell tumor cell line KGN has been used to demonstrate that 
lncRNA H19 binds to miR-19b, resulting in upregulation of CTFG, increase in cell prolif-
eration,d reduction in the rate of apoptosis in these cells [155]. 
6.2. HOTAIR 
HOX transcript antisense RNA (HOTAIR) has shown some potential as a diagnostic 
and predictive biomarker. This lncRNA acts as a molecular scaffold and binds the Poly-
comb Repressive Complex 2 (PRC2) on its 5′ domain and the lysine-specific histone de-
methylase 1A (LSD1)/CoREST/REST complex on its 3′ domain, bringing them in close 
proximity and methylating lysine 27 and demethylating lysine 4 of histone H3, leading to 
consequent gene silencing [156,157]. Expression of HOTAIR promotes proliferation, stem-
ness, and epithelial-to-mesenchymal transition of OC cells [158–160]. The transcription of 
HOTAIR is induced by estrogen, making it a relevant lncRNA in the context of gyneco-
logical cancers [161]. It has been associated with poor prognosis and tumor metastasis in 
epithelial ovarian cancer and cervical cancer [162–164]. Its prognostic value has been eval-
uated by a meta-analysis in four estrogen-dependent tumor types (breast, ovarian, cervi-
cal, and endometrial), and it may be a predictor of poor prognosis [165]. Specific genetic 
variants of HOTAIR may in some populations affect OC susceptibility [166,167]. HOTAIR 
expression is also associated with chemoresistance in clinical samples and in vitro models, 
and its knockdown can lead to increased sensitivity to cisplatin and carboplatin both in 
vitro and on a mouse xenograft model [97,159,168,169]. A peptide nucleic acid (PNA) de-
signed to specifically block the activity of HOTAIR has been successful in reducing ovar-
ian tumor growth in vitro and in vivo, and improved survival of xenograft mice, and has 
been suggested as a potential new therapeutic approach for the treatment of OC [170]. The 
Cancers 2021, 13, 5040 13 of 36 
 
 
potential use of this lncRNA as a biomarker has led to the development of various meth-
ods for detection of this lncRNA from samples derived from patients with OC, primarily 
plasma [171,172]. 
6.3. MALAT1/NEAT2 
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as 
nuclear-enriched abundant transcript 2 (NEAT2), is another lncRNA significantly overex-
pressed in various cancers [173,174], and has been extensively studied in OC. A meta-
analysis revealed that MALAT1 could be a novel biomarker in various cancers, including 
ovarian [175]. It can be detected in the plasma, and it has been suggested as a potentially 
useful marker for OC metastases [176]. Metastatic EOC cells show increased expression 
of MALAT1 and increased secretion through their exosomes, and this activates angiogen-
esis-related genes in the endothelial cells [105]. MALAT1 is highly overexpressed in OC 
and is associated with the FIGO stage. Its overexpression leads to increased cell prolifer-
ation, migration, and invasion [177,178]. It can act through sponging several different 
miRNA molecules, all resulting in increased proliferation and survival of cancer cells: 
miR-22 [179], miR-506 [180], miR-200c [181], miR-143-3p [182], miR-200a [96], miR-211 
[183], miR-503-5p [184]. MALAT1 has also been found to downregulate RBFOX2, which 
leads to the alternative splicing of the KIF1B and production of the pro-apoptotic long 
isoform of KIF1B, ultimately resulting in inhibition of anoikis [185]. 
Other signaling pathways which are directly or indirectly affected by MALAT1 in-
clude the PI3K-AKT pathway [186] and the ERK/MAPK pathway [187]. MALAT1 has also 
been implicated in drug resistance of OC, as it was found upregulated in cisplatin-re-
sistant OC cells, where it sponges miR-1271-5p, leading to upregulation of E2F5 and in-
creased proliferation, migration, and invasion [188]. MALAT1 is also upregulated in OC 
spheroids when compared to their adherent counterparts, suggesting a role of MALAT1 
in cancer cell stemness [189]. Knockdown of MALAT1 can restore chemosensitivity of OC 
to cisplatin through the inhibition of the NOTCH1 signaling pathway [190]. Apart from 
the effects of MALAT1 investigated in OC in general, some ROCs have also been investi-
gated. Experiments on the KGN cell line demonstrated that MALAT1 is upregulated in 
these cells and involved in the maintenance of proliferation and viability as well as inhi-
bition of autophagy [191]. MALAT1 knockdown induces upregulation of p21, p53, p-JNK, 
and p-ERK1/2, and downregulation of CDK2, cyclin D1, and p-P38 MAPK protein levels 
[187]. In choriocarcinoma MALAT1 binds to miR-218, leading to upregulation of FBXV8 
oncogene and cell proliferation [192]. In KGN cells knockdown of MALAT1 results in in-
hibition of the ERK/MAPK pathway leading to the inhibition of cell proliferation and cell 
cycle progression [187]. 
6.4. MEG3 
Maternally expressed 3 (MEG3) lncRNA has been reported as a tumor suppressor. 
Its major role is in the positive regulation of the tumor suppressor gene TP53 [193]. MEG3 
is downregulated in many cancers, such as breast [194], cervical [195], gastric [196], lung 
[197], and EOC [198]. Downregulation in EOC is achieved through hypermethylation of 
the MEG3 promoter, as treatment with demethylating agent 5-aza-2-deoxycytidine in-
creases MEG3 expression. Increased expression of MEG3 suppresses proliferation and 
growth and induces apoptosis, and suppresses tumorigenesis in vivo [95,198]. Upregula-
tion of MEG3 induces expression of PTEN and LAMA4, leading to inhibition of cell pro-
liferation, cell cycle arrest, and induction of apoptosis [199,200]. On the other hand, high 
expression of MEG3 is associated with better progression-free survival and overall sur-
vival in HGSOC, even though the same authors demonstrated that MEG3 is downregu-
lated in HGSOC cell lines compared to the normal fallopian tube and ovarian cell lines, 
and upregulation of MEG3 in HGSOC cells leads to inhibition of tumor growth in vitro 
and in vivo [201]. It can bind directly to ATG3 mRNA and protect it from actinomycin D-
induced degradation [95]. MEG3 is one of the three signature lncRNA that can be used to 
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predict cisplatin resistance in OC. Upregulated PVT1 and downregulated TUG1 and 
MEG3 have high sensitivity and specificity in predicting chemoresistance and are nega-
tively associated with OS and progression-free survival [202]. Sensitivity to cisplatin can 
be restored with curcumin treatment, as it leads to demethylation of the MEG3 promoter, 
sponging of miR-214 by MEG3, and consequent reduction of drug resistance [203]. MEG3 
expression can be negatively regulated by another lncRNA: AGAP2-AS1, which is upreg-
ulated in OC and participates in cancer cell proliferation [204]. 
6.5. NEAT1 
Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) is another lncRNA that is over-
expressed in various cancers, including OC. NEAT1 is upregulated in OC, positively cor-
related with FIGO stage, tumor grade, and distant metastasis. NEAT1 expression level is 
an independent factor in predicting the overall survival of OC patients [205]. A meta-anal-
ysis of 1354 patients from 11 studies revealed that NEAT1 expression is indeed signifi-
cantly associated with poor overall survival, larger tumor size, lymph node metastasis, 
distant metastasis, TNM-stage, poor differentiation, and invasion depth [206]. Based on 
all this, NEAT1 has been proposed as a prognostic biomarker in breast, ovarian, cervical, 
endometrial, and vulvar cancers [207]. It interacts with several miRNAs: miR-34a-5p [208], 
miR-124-3p [209], miR-382-3p [210], miR-506 [211], miR-1321 [212], miR-4500 [213] and 
miR-365 [214]. NEAT1 is also involved in the development of resistance. In the platinum-
resistant OC cells, NEAT1 binds miR-770-5p, leading to upregulation of PARP1. Knock-
down of NEAT1 expression results in a reduction in xenograft tumor growth as well as 
increases sensitivity to cisplatin [215]. In the case of paclitaxel (PTX) resistance, NEAT1 is 
upregulated in PTX-resistant OC tissues and cells and binds to miR-194. NEAT1 knock-
down enhanced the sensitivity of cells to PTX through the miR-194/ZEB1 axis [216]. The 
potential of NEAT1 as a possible diagnostic marker has been proposed in several cancers, 
such as prostate [217] and breast [218]. For EOC, a serum biomarker panel that combines 
gene and protein expression was proposed as a method for early detection of EOC, and 
NEAT1 is one of the proposed lncRNA in this panel [219]. 
6.6. UCA1 
Urothelial cancer associated 1 (UCA1) is an oncogenic lncRNA found to be upregu-
lated in many solid tumors. A meta-analysis revealed that upregulation of UCA1 is nega-
tively associated with overall survival and progression-free survival in many cancers, in-
cluding OC [220]. UCA1 acts as a sponge for miR-485-5p, which in turn upregulates the 
levels of MMP14, and this upregulation of MMP14 is an important factor in OC metastasis 
[221,222]. It can also bind directly to AMOT, a known regulator of YAP, and promote 
activation of YAP and subsequent transcription of target genes [223]. It has been suggested 
as a potential new biomarker and therapeutic target of OC, especially in the context of 
drug resistance where it may serve as an indicator of response to therapy [224,225]. For 
example, UCA1 expression induces cisplatin resistance in OC cell lines. This could be me-
diated through the upregulation of SRPK1 [226] or the miR-143/FOSL2 axis [227]. 
Paclitaxel resistance has also been associated with UCA1 expression, by regulating the 
miR-654-5p/SIK2 axis [228] and/or the miR-129/ABCB1 axis [229]. 
6.7. XIST 
X inactive specific transcript (XIST) regulates X-chromosome inactivation, by acting 
as a scaffold for repressive epigenetic factors, and as many as 30 different RNA-binding 
proteins are predicted to bind with XIST. XIST RNA contains structured regions, or Xist 
motifs, which are crucial for its function. Of these, the A-repeat (RepA) folds into a stem-
loop structure and is required for gene silencing [230]. A meta-analysis has demonstrated 
that XIST is associated with poor overall survival, larger tumor size, increased distant 
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metastases, and advanced tumor stage in a range of cancers [231]. In OC, there are con-
flicting results. XIST has been found to be downregulated and correlated to better prog-
nosis in OC in one study [232], while another study shows that XIST was upregulated in 
OC tissues and cell lines and is suggested as an independent predictor of prognosis for 
OC patients [233]. Studies regarding the role of XIST in OC are also contradictory–some 
claim upregulation of XIST leads to stimulation and increased proliferation of OC cells, 
while others claim it suppresses OC proliferation and tumor growth [233–237]. 
Table 2. The lncRNAs frequently involved in OCs and their mechanisms of action. OC type includes rare OC types (GCT–
granulosa cell tumor) and common OC types (HGSOC–high-grade serous ovarian carcinoma, EOC–epithelial ovarian 
cancer, EC–endometrioid carcinoma), while the abbreviation OC refers to papers that did not define specific OC subtypes, 
and OCSC refers to ovarian cancer stem cells. 
lncRNA Target OC Type Mode of Action Effect Role Reference 
H19 
miR-370-3p EC, HGSOC ceRNA Promotes TGFB1-Induced EMT Oncogene [144] 
miR-324-5p EC ceRNA Promotes Warburg Effect through PKM2 Oncogene [104] 
miR-19b GCT ceRNA 
Increased Expression of CTGF, Resulting in Cell 
Proliferation and Reduced Rate of Apoptosis 
Oncogene [155] 
let-7 EC, OCSC ceRNA Promotes Tumor Cell Migration and Invasion Oncogene [145] 
HOTAIR PRC2 / Scaffold 
The trimethylation of the H3K27 Histone and 




miR-22 EOC ceRNA 
Increased Cell Proliferation, Migration, Invasion, 
Tumor Growth, and Metastasis 
Oncogene [179] 
miR-506 OC ceRNA Upregulation of iASPP and Cell Proliferation Oncogene [180] 
miR-200c EC, EOC ceRNA Increased Invasive Capacity Oncogene [181,238] 
miR-143-3p EOC ceRNA Upregulation of CMPK Oncogene [182] 
miR-200a EC ceRNA Promotes Autophagy and Invasion Oncogene [96] 
miR-211 EC, HGSOC ceRNA 
Upregulation of PHF19, Leading to OC Progres-
sion 
Oncogene [183] 
miR-503-5p EOC ceRNA 
Promotes Proliferation and Inhibits Apoptosis 




HGSOC, EC ceRNA 
Upregulation of E2F5 Expression, Mediates DPP-
Resistant OC Development 
Oncogene [188] 
SRSF1 EOC Scaffold 
Downregulation of RBFOX2, Leading to Alterna-
tive Splicing of KIF1B Leading to Production of 
the Pro-Apoptotic Isoform 
Oncogene [185] 
YAP EC ceRNA 
Inhibition of Nucleus-Cytoplasm Translocation, 
Resulting in Enhanced Activity and Promotion of 
Stemness Phenotype 
Oncogene [189] 
AMPK GCT Unknown 
Proliferation, Viability, Inhibition of Autophagy, 
Downregulation of AMPK 
Oncogene [191] 
multiple GCT Signal Molecule 
Downregulation of p21, p53, p-JNK, p-ERK1/2; 
Upregulation of CDK2, Cyclin D1, p-P38 MAPK 
Oncogene [187] 
MEG3 
ATG3 EOC Scaffold 









PTEN EOC Unknown 
Upregulation of PTEN, Inhibition of Cell Prolifer-







Downregulation of EGRF, Inhibition of Prolifera-




miR-30e-3p OC ceRNA 
Upregulation of LAMA4, Reduced Proliferation, 




miR-205-5p OC ceRNA 
Inhibition of Cell Viability, Migration, and Inva-




NEAT1 miR-34a-5p OC ceRNA Promotes Proliferation by Upregulating BCL2 Oncogene [208] 
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miR-124-3p OC ceRNA 
Promotes Cell Proliferation and Invasion, NEAT1 
Expression is Stabilized by HuR Protein 
Oncogene [209] 
miR-382-3p OC ceRNA Promotes ROCK1-Mediated Metastasis Oncogene [210] 
miR-506 EOC ceRNA 
Promotes Cell Proliferation and Migration, 
NEAT1 is Stabilized by LIN28B 
Oncogene [211] 
miR-1321 OC ceRNA 
Increased Expression of TJP3, Enhances EMT, In-
vasion, and Migration 
Oncogene [212] 
miR-4500 OC ceRNA 
Increased Expression of BZW1, Enhances Cell 
Proliferation, Colony Formation, Migration, Inva-
sion, and Glycolysis, Reduces Apoptosis 
Oncogene [213] 
miR-365 EC, HGSOC ceRNA 
Increased Expression of FGF9, Promotes Cell Pro-
liferation and Angiogenesis 
Oncogene [214] 
UCA1 
miR-485-5p EOC ceRNA 
Increased Expression of MMP14, Possible Role in 
Metastasis of OC 
Oncogene [221] 
AMOT EOC ceRNA 
Enhances AMOT-YAP Interaction, Activation of 
YAP Target Genes,  
Oncogene [223] 
miR-143 OC ceRNA 
Upregulation of FOSL2, Increased Cisplatin Re-
sistance 
Oncogene [227] 
miR-654-5p OC ceRNA Upregulation of SIK2, Resistance to Paclitaxel Oncogene [228] 
miR-129 OC ceRNA Upregulation of ABCB1, Resistance to Paclitaxel Oncogene [229] 
XIST 
miR-149-3p EOC ceRNA 
Upregulation of FOXP3 Leading to OC Cell Pro-
liferation 
Oncogene [235] 
miR-101-3p HGSOC ceRNA 
Upregulation of C/EBPα and KLF6 Leading to 
Macrophage Polarization to Affect Cell Prolifera-
tion of OC 
Oncogene [237] 
miR-214-3p HGSOC ceRNA 
Suppression of Cell Proliferation, Invasion, In-
creased Chemosensitivity, Inhibition of Tumor 




miR-106a OC ceRNA 
Decrease in Cell Proliferation and Activation of 




6.8. Other lncRNAs Involved in Rare Ovarian Cancers 
LncRNA growth arrest-specific 5 (GAS5) is upregulated in the plasma of patients 
with polycystic ovary syndrome (PCOS). This was also demonstrated in the ovarian gran-
ulosa cell tumor cell line KGN, where it leads to upregulation of IL6, and decreased apop-
tosis rate of these cells [241]. HLA complex P5 (HCP5) promotes cell proliferation and 
inhibits apoptosis in the KGN cell line through the miR-27a-3p-IGF1 axis [242]. In contrast, 
NPTN intronic transcript 1 (NPTN-IT1, or lncRNA-LET) is downregulated in KGN cells, 
and its overexpression inhibited cell viability and migration and promoted apoptosis 
[243]. 
Upregulation of long intergenic non-protein coding RNA 324 (LINC00324) has been 
found in immature ovarian teratocarcinoma (IOT) tissues and cells. LINC00324 acts as a 
miR-214-5p sponge, thereby removing its inhibition of CDK6, CCND1, MDM2, and 
MDM4, consequently increasing IOT cell proliferation and decreasing apoptosis [244]. 
A study by Yan et al., identified neuroblastoma-associated transcript 1 (NBAT1) as a 
marker of favorable prognosis in OC. The study included 46 serous OC and 11 OC tumors 
of different origins, but there was no additional information on these other subtypes. 
However, the authors state that there was no difference between histological subtypes, 
suggesting that this marker is applicable for ROCs as well [245]. 
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Table 3. Other lncRNAs with a role in ROCs. ROC analyzed in these papers include GCT–granulosa cell tumors, IOT-
immature ovarian teratocarcinoma, and undefined (other). 
lncRNA Target OC Type 
Mode of  
Action 
Effect Role Reference 
GAS5 IL6 GCT Unknown Upregulation of IL6, Decreased Apoptosis Oncogene [241] 
HCP5 miR-27a-3p GCT ceRNA Proliferation, Inhibition of Apoptosis Oncogene [242] 
NPTN-IT1 NF90 GCT Scaffold 


















7. Circulating lncRNAs as Diagnostic and Prognostic Biomarkers for OCs 
Liquid biopsies are considered a minimally invasive means for managing cancer pa-
tients, and they can be applied in diagnosis, follow-up, and prediction to therapy. Liquid 
biopsies can be used for the detection of circulating tumor cells (CTCs), cell-free tumor 
DNA (ctDNA), and non-coding RNAs [246]. Circulating non-coding RNAs (miRNA and 
lncRNAs) have been proposed as potential biomarkers for the early detection of OC. In 
particular, multiple miRNA panels have been proposed as screening tools in clinical prac-
tice [247]. Several publications examine the possible role of lncRNAs in the diagnosis, pre-
diction, and prognosis of OCs. Non-coding RNAs can be secreted from EOC cells via ex-
osomes, and in turn exosomes from the serum of patients can be used for detection of 
these non-coding RNAs. Elevated exosomal levels of MALAT1 in the serum of patients 
were highly correlated with advanced and metastatic subtypes of EOC, and an independ-
ent predictive factor for overall survival [105]. Exosomal HIF1A-AS2 levels from the serum 
of EOC patients have been associated with poorer overall survival and suggested as a non-
invasive predictive biomarker for unfavorable prognosis [248]. LOXL1-AS1 was analyzed 
in the plasma of EOC patients, and its expression was associated with advanced FIGO 
stage, distant metastases, and short overall survival. It was proposed to be an independent 
diagnostic and prognostic factor in EOC [249]. A meta-analysis, which encompassed 1732 
OC patients and 3958 controls, evaluated the diagnostic accuracy of ctDNA, miRNAs, and 
lncRNAs and found, albeit on a small number of studies, that lncRNAs were more accu-
rate than miRNAs in diagnosing OC, with similar specificities. The authors claim that 
combining ctDNA, miRNA, and lncRNA biomarkers is the best option as it avoids the 
shortcomings of single biomarkers regarding sensitivity and specificity [250]. The major 
drawbacks and challenges in the detection of lncRNAs from liquid biopsies, and their use 
as biomarkers, is their low concentration in the serum/plasma and potential contamina-
tion with genomic DNA. Even though nowadays RNA extraction kits are able to remove 
the bulk of contaminating genomic DNA, nevertheless care must be taken during sample 
preparation, as contamination with genomic DNA in RNA preparations can lead to a false 
positive signal in qRT-PCR assays. This is especially true for lncRNAs encoded by a single 
exon, such as MALAT1 [251]. Soda et al., have recently demonstrated that HOTAIR can be 
detected from plasma samples using electrochemical detection, and they propose that this 
assay could be used in a clinical setting for the detection of various lncRNA biomarkers 
[172]. It is also possible to detect microproteins encoded by lncRNAs in the extracellular 
vesicles in human plasma samples, and these microproteins could be used as diagnostic 
markers [252]. More studies of different circulating biomarkers in OCs are needed to as-
semble a good panel of miRNA/lncRNA targets for the diagnosis of OC and for determin-
ing their response to therapy. This could lead to better early detection and a personalized 
approach to therapy with a better outcome for OC patients. 
Expression levels of circulating extracellular or exosome/EV lncRNAs associated 
with body fluids such as plasma/serum could serve as a potential biomarker for routine 
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usage and a complementary liquid biopsy for the risk of ovarian tumor metastasis, recur-
rence, drug resistance, and potentially early detection. As single markers sometimes lack 
sensitivity and specificity, designing biomarker panels has been suggested as a good op-
tion for early detection, diagnosis, and prediction of recurrence. Such panels of lncRNAs 
have already been proposed for hepatocellular [253], liver [254], bladder [255,256], breast 
and cervical cancer [257]. A lncRNA panel as a candidate prognostic biomarker for OC 
has been proposed by Zhan et al. [258], but the focus was mainly on the construction of 
panels that can assess the response to therapy of OC patients, for example for platinum-
based chemoresistance [259,260] or paclitaxel resistance [261]. LncRNA has the potential 
to be companion diagnostic tools alongside ctDNA and even CTCs in predicting recur-
rence and resistance, but how they could be incorporated into a screening program re-
mains to be determined. In addition, a panel distinguishing between rare OC subtypes 
could prove to be most beneficial for diagnostic purposes. 
8. Strategies for Targeting lncRNAs as a Treatment for OCs 
The important role of lncRNAs in various biological processes related to carcinogen-
esis, together with their cancer-specific expression patterns, has made lncRNAs promising 
therapeutic targets. Therefore, many strategies have been developing for their targeting 
[262,263]. Generally, there are two main approaches, which have already been applied for 
targeting different lncRNAs in OC: to alter their expression level or to inhibit their inter-
actions with other macromolecules [13]. 
Oncogenic lncRNAs are overexpressed in cancers so their expression can be sup-
pressed using various, mostly nucleic acids-based techniques. Most commonly used 
methods are based on RNA interference (RNAi), like small interfering RNAs (siRNAs) or 
short/small hairpin RNAs (shRNAs) [264]. siRNAs are short, double-stranded (ds) RNAs 
that unwind into single strands (ss), bind to the RNA-induced silencing complex (RISC), 
and base-pair with targeting lncRNAs. That leads to Argonaute protein-dependent deg-
radation of the target transcripts. Chemically synthesized siRNAs are usually directly de-
livered into the cytoplasm through transfection. shRNAs are produced as ss molecules 
50–70 nucleotides long which form hairpin-like structures. They are usually encoded in 
DNA vectors and introduced into cells by plasmid transfection or viral transduction. They 
undergo processing and exert their mechanism of action similarly to siRNAs [265]. Pre-
sumably, all lncRNAs characterized in Tables 2 and 3 as oncogenes, i.e., those which are 
over-expressed in OC and thus contribute to its initiation, tumorigenesis, or metastasis, 
could be targeted using RNAi methods. LncRNA silencing by siRNA or shRNA is proba-
bly the most used method for deducing lncRNA function in vitro [266]. 
LncRNA expression can also be suppressed using antisense oligonucleotides (ASOs), 
locked nucleic acid GapmeRs (LNA GapmeRs), or antagonists to natural antisense tran-
scripts (antagoNATs) [267]. ASOs are ss antisense oligonucleotides made up of a DNA 
stretch at the central part with flanking RNA nucleotides. The DNA part with the target 
lncRNA, through Watson-Crick base pairing, forms a DNA/RNA heteroduplex which is 
cleaved by endogenous RNase H1 [268]. For instance, targeting lncRNA MALAT1, which 
is overexpressed in both common and rare OCs, by ASOs, inhibited tumor growth and 
metastasis of breast [269] and lung cancer [270]. LNA GapmeRs share structural and func-
tional similarities with ASOs but have chemically modified LNA in flanking parts which 
increases their binding affinity and nuclease resistance [271]. LNAs have been constructed 
for targeting XIST [272], a lncRNA both up- and down-regulated in EOCs. NATs are 
coded from the opposite strand of the host gene locus and regulate expression of either 
sense transcripts of the same locus (cis-NATs) or transcripts from other genomic loci 
(trans-NATs). They mediate transcriptional silencing through histone-modifying com-
plexes [273]. AntagoNATs are ss oligonucleotides designed to inhibit sense-antisense 
transcripts interactions and thus they can eliminate the epigenetic silencing effect of 
lncRNAs that act as NATs [274]. The first successfully applied antagoNAT was against 
BDNF-AS, a NAT that represses transcription of brain-derived neurotrophic factor 
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(BDNF) gene [274]. This approach could potentially be used for regulating the expression 
of ovarian BDNF, which promotes survival, migration, and attachment of tumor precur-
sors originated from TP53-mutated fallopian tube epithelial cells, precursors of HGSOC 
[275]. AntagoNATs could also be designed for targeting other NATs commonly dysregu-
lated in common and rare OCs, such as HOTAIR, MALAT1, MEG3, and GAS5 [273]. 
Other methods used for silencing lncRNA expression are mixmers and deoxy/ribo-
zymes. Mixmers are built of chemically modified nucleotides like LNAs and different 
types of monomers. They sterically inhibit interactions between lncRNAs, ribonucleopro-
teins, or nucleic acids. They are used for preventing the formation of epigenetic remodel-
ing complexes, altering gene expression and alternative splicing, repairing defective 
RNAs, and restoring protein production [276]. So far, the best-described example is a mix-
mer consisting of LNA interspersed with 2′-O-methyl nucleotides with a high-affinity for 
SMN-AS1, an antisense transcript that represses expression of survival motor neuron 2 
(SMN2) gene by recruiting the PRC2 to its locus [277]. For treating OCs, a similar approach 
could be used, for instance, for targeting interactions between PRC2 and HOTAIR [156] or 
XIST [278]. Deoxyribozymes are enzymatic ssDNA molecules that bind target RNA 
through Watson-Crick base pairing and catalyze RNA cleavage (ribonucleases) [279]. Sim-
ilarly, there exist engineered ribozymes that have better catalytic activities and more spe-
cific substrate recognition domains [280]. A site-specific deoxyribozymes have been de-
signed to cleave RNAs that have N6-methyladenosine (m6A) modifications [281]. In the 
meantime, it was discovered that many lncRNAs such as MALAT1 [282], XIST [283], HO-
TAIR [284], GAS5 [285], or DANCR [286] contain one to several m6A modifications, and 
thus deoxyribozymes could be used as therapeutics for OC [287]. 
Gene-editing methods like zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and clustered regularly interspaced short palindromic re-
peats/CRISPR-associated protein 9 (CRISPR/Cas9) system can be used to suppress 
lncRNA expression [288,289]. It is worth noting that, unlike protein-coding genes, lncRNA 
genes are not vulnerable to small insertions, deletions, or frameshift mutations so their 
genes must be edited to a much larger extent. In addition, lncRNA expression can steri-
cally be repressed by CRISPR interference (CRISPRi) [290]. CRISPRi uses guide RNA 
(gRNA) for recognizing the target gene and catalytically dead Cas9 (dCas9) protein with-
out endonuclease activity for blocking initiation or elongation of transcription. Similarly, 
CRISPR activation (CRISPRa) can be used for sequence-specific activation of gene expres-
sion. Besides several large scales, genome-wide deletion of up to several thousand 
lncRNA loci [291,292], CRISPRi was successfully used for knocking out particular, single 
lncRNA such as MALAT1 [293], XIST [294], HOTAIR [295], NEAT1 [296] or UCA1 [297]. 
Furthermore, instead of transcriptional silencing of the whole lncRNA gene, CRISPR/Cas9 
could be also used for “repairing” alleles of lncRNAs genes found to be associated with 
ovarian cancer susceptibility, such as HOTAIR polymorphism rs920778 [298]. 
Manipulation with lncRNAs expression levels with any of the aforementioned meth-
ods could be used to interfere with the function of lncRNAs as miRNA sponges. Increased 
expression of lncRNAs that bind oncomiRs or decreased expression of lncRNAs that bind 
tumor-suppressor miRNAs could normalize gene regulatory network and signaling path-
ways, and reverse malignant phenotype, just like using miRNA mimics or antagomiRs 
[299]. For instance, since the expression of ceRNA SNHG5 is reduced in paclitaxel-re-
sistant OC patients, either SNHG5 overexpression or miR-23a inhibition could enhance 
paclitaxel sensitivity [300]. Similarly, ceRNA UCA1 can sponge miR-654-5p, while its 
knockdown enhances miR-654-5p expression, which reduces ovarian tumor cells viability 
in vitro and in vivo [301]. 
As mentioned above, the second general therapeutic approach for targeting lncRNAs 
in OC would be to abolish their function by inhibiting their interactions with other mac-
romolecules, either through competition or steric blockade. There are several approaches 
including aptamers, nanobodies, small molecules, and RNA decoys [302]. Aptamers are 
short (up to 200 nucleotides) ss DNA or RNA molecules with high specificity and affinity 
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for their targets and are considered nucleic acid analogs of antibodies [303]. However, 
they have better tissue penetration, lower immunogenicity, and in vivo stability. They act 
through dynamic three-dimensional structure, by recognizing the secondary structure of 
lncRNAs, and thus interfering with lncRNA-protein interactions [304]. For instance, there 
exist aptamers against HOTAIR [305] and H19 [306], which could be used as OC thera-
peutics. Nanobodies are heavy chain-only antibodies (HCAbs), found naturally in sharks 
and camelids, that is built of a single variable domain (VHH), which is similar to the Fab 
fragment of human IgG antibodies and thus non-immunogenic [307]. They have both high 
affinity and specificity and the potential to interrupt lncRNA-RBP interactions [308]. 
Nanobodies can be designed to specifically target highly structured RNA molecules [309], 
and since it is known that many lncRNAs such as MALAT1 [310], NEAT1 [311], XIST [230], 
or HOTAIR [312] are well-structured, this approach could be used for treating OC types 
in which those lncRNAs are overexpressed. Small molecules (chemical compounds), by 
binding to either lncRNAs or RNA-binding proteins (RBPs), can change their secondary 
or tertiary structures or mask protein-binding sites on lncRNAs or lncRNA-binding do-
mains of RBPs, and thus disrupt interactions between them [313,314]. Similar to nanobod-
ies, highly structured parts of lncRNAs can also be targeted by small molecules. Therefore, 
the use of high-throughput screening identified a small molecule ellipticine that can in-
hibit interactions between HOTAIR-EZH2 and BDNF-AS-EZH2 [315]. Furthermore, sev-
eral small molecules have been discovered that can target MALAT1 [316,317]. RNA decoys 
or imitators of lncRNAs could be designed to act through binding to and sequestering of 
proteins, to disrupt the creation of functional lncRNA-RBP complexes [318]. One such ex-
ample is an anti-HIV decoy that targets the HIV-1 Tat protein. It has a trans-activation 
response (TAR) element RNA hairpin and binds to the Tat protein. This decoy localizes 
in the nucleolus while natural TAR RNA is localized in the nucleus [319]. Another exam-
ple is a mimic of HULC, a lncRNA that interacts with phenylalanine hydroxylase (PAH) 
and modulates its function. HULC depletion causes reduced enzymatic activities of PAH, 
which is a characteristic of metabolic disorder phenylketonuria. The introduction of HULC 
mimics successfully restores the function of that liver lncRNA and reduces excess phenyl-
alanine levels [320]. Therefore, this therapeutic approach could be used for treating OC 
types in which reduced levels of certain lncRNA, e.g., those that were in Tables 2 and 3 
classified as a tumor suppressor, is a cause for OC initiation, tumorigenesis, or metastasis. 
Regulatory regions of lncRNAs could be also used for constructing more efficient 
drugs. There exists a DNA plasmid called H19-DTA (BC-819) that carries the gene for A 
subunit of diphtheria toxin under the regulation of the H19 promoter and it is used for 
treating cancers with high H19 expression such as OC [321]. Its safety and efficacy for 
treating ovarian and peritoneal cancer patients with advanced recurrent disease had al-
ready been proven in the Phase I/IIa clinical trial [322]. 
All previously described methods consider targeting a lncRNA of interest as a pri-
mary therapeutic goal for treating OCs. However, targeting lncRNAs could also be used 
to enhance the efficiency of already applied therapeutic regimes, since for many OC-re-
lated lncRNAs described in this paper their involvement in resistance to radio- and chem-
otherapy was mentioned. This has been comprehensively reviewed in [323,324]. 
Although constantly on the rise in recent years [325], RNA-based or RNA-targeted 
therapeutic approaches still have many limitations, such as inefficient delivery to the tar-
get tissue, toxicity and immunogenicity, and off-target effects (non-selectivity). Over the 
past decade, in parallel with the development of novel RNA therapeutics, promising ap-
proaches have been developed to overcome these hurdles and to boost their success [326]. 
Hopefully, this will bring to more (successful) clinical trials for targeting long non-coding 
RNAs as a potential therapeutic approach for the treatment of OCs. 
9. Online Resources for lncRNA Research 
Expanding interest in lncRNA research has led to the accumulation of a vast amount 
of knowledge that has to be properly analyzed, organized, and made available for the 
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wider scientific community. Therefore, a constantly growing number of web resources 
and bioinformatical tools have been developed that can help many different aspects of 
lncRNA research [327,328]. However, for an ordinary wet-lab lncRNA cancer researcher 
without advanced computational skills, databases, and online tools would be the most 
useful [329]. Unlike miRbase for microRNAs [330], there is still no primary, central repos-
itory for lncRNAs. In Table 4 there is a shortlist of the best known and most used lncRNA 
web resources. 
Table 4. A short overview of online resources useful for lncRNA research in cancer. 
Type Web Address Reference 
General lncRNA Databases 
RNAcentral https://rnacentral.org/ [331] 
LNCipedia https://lncipedia.org/ [332] 
LncBook http://bigd.big.ac.cn/lncbook/index [333] 
lncRNAdb http://lncrnadb.org/ [334] 
lncRNome http://genome.igib.res.in/lncRNome/ [335] 
GENCODE https://www.gencodegenes.org/ [55] 
General Expression Databases 
GTEx https://gtexportal.org/home/ [336] 
GEO https://www.ncbi.nlm.nih.gov/geo/ [337] 
TCGA https://portal.gdc.cancer.gov/ [338] 
Expression Atlas https://www.ebi.ac.uk/gxa/home [339] 
The lncRNA-Specific Expression Databases 
NONCODEV5 http://v5.noncode.org/index.php [340] 
NRED http://jsm-research.imb.uq.edu.au/nred/cgi-bin/ncrnadb.pl [341] 
LncExpDB https://bigd.big.ac.cn/lncexpdb/ [342] 
LncSpA http://bio-bigdata.hrbmu.edu.cn/LncSpA/ [343] 
General Disease- and Cancer-Specific lncRNA Databases 
TANRIC https://www.tanric.org/ [344] 
LncRNADisease 2.0 http://www.rnanut.net/lncrnadisease/ [345] 
Lnc2Cancer 3.0 http://www.bio-bigdata.com/lnc2cancer/ [346] 
lncRNASNP2 http://bioinfo.life.hust.edu.cn/lncRNASNP/ [347] 
Lnc2Catlas https://lnc2catlas.bioinfotech.org/ [348] 
Function-Specific and Other Useful lncRNA Databases 
DIANA-LncBase v3 https://diana.e-ce.uth.gr/lncbasev3/home [349] 





LncRNAWiki http://lncrna.big.ac.cn [352] 
lncRNA Blog https://www.lncrnablog.com/ - 
10. Conclusions and Future Perspectives 
Recently we celebrated the 20th anniversary of publishing the draft human genome 
sequence. Initially, only about 2% of the human genome was reported to comprise pro-
tein-coding genes, and the rest referred to as “junk” DNA, it has become increasingly ev-
ident that this “junk” DNA is a goldmine for many regulatory non-coding transcripts. 
One type of such transcript is the lncRNAs. Consequently, their mechanisms of action and 
the molecular processes which they regulate are still being unraveled. As anticipated, their 
causative roles in the development and progression of many human neoplasms, including 
OCs, are becoming increasingly evident. 
The major drawback in discovering the (in)distinctive roles of lncRNAs in common 
and rare OCs is the lack of studies that clearly and properly separate the OC subtypes. 
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One potential reason for that could be both clinicians’ and researchers’ inexperience in 
diagnosing rare gynecological cancers. On the other hand, the manuscript reviewers 
should insist that authors need to put more effort into describing their clinical samples. 
Hopefully, international collaborations such as the GYNOCARE COST Action will con-
tribute to a more unified and standardized diagnosis and classification of ROCs [1]. 
Long non-coding RNA molecules are promising diagnostic and prognostic bi-
omarkers for ROCs [353]. Currently, we have been witnessing an accelerated develop-
ment and an increased efficiency of RNA-bases therapeutics. Further in-depth knowledge 
about lncRNAs should direct researchers and pharmaceutical companies in the post-
COVID era to become more interested in lncRNAs as potential therapeutic agents or ther-
apeutic targets. These emerging technologies and approaches could certainly improve the 
quality of life and outcome of many women with ROCs. 
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Abbreviations 
BEP bleomycin, etoposide, and cisplatin 
CAF cancer-associated fibroblasts 
ceRNA competing endogenous RNA 
CSC cancer stem cells 
EC endometroid carcinoma 
EMT epithelial to mesenchymal transition 
EOC epithelial ovarian cancer 
FIGO Fédération Internationale de Gynécologie et d’Obstétrique 
GCT granulosa cell tumor 
HGSOC high-grade serous ovarian cancer 
HOTAIR HOX transcript antisense RNA 
IOT immature ovarian teratocarcinoma 
LGSOC low-grade serous ovarian cancer 
lincRNA long intergenic non-coding RNA 
lncRNA long non-coding RNA 
MALAT1 metastasis-associated lung adenocarcinoma transcript 1 
MSC mesenchymal stem cell 
MET mesenchymal to epithelial transition 
miRNA/miR microRNA 
MOC mucinous ovarian carcinoma 
NAT natural antisense transcript 
ncRNA non-coding RNA 
OC ovarian cancer 
OCCC ovarian clear cell carcinoma 
OCSC ovarian cancer stem cells 
PCOS polycystic ovary syndrome 
PRC Polycomb Repressive Complex 
RNAi RNA interference 
ROC rare ovarian cancer 
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siRNA small interfering RNA 
shRNA short hairpin RNA 
XIST X-inactive specific transcript 
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